摘要
双调蛋白是表皮生长因子受体的配体，在多种组织中表达，与多种肿瘤的发生、进展和转移密切相关。在肺癌的临床研究中，双调蛋白可作为非小细胞肺癌患者的预后指标。此外，双调蛋白与表皮生长因子受体酪氨酸激酶抑制剂的治疗敏感性及耐药性有关。以双调蛋白为靶点的药物展现出了一定的抗肿瘤特性。
Amphiregulin is the ligand of epidermal growth factor receptor. It＇ s widely expressed in many tissues and is involved in the oncogenesis, progression and metastasis of tumors. In the clinical study of lung caner, amphiregulin is a prog- nostic marker for NSCLC patients. Furthermore, amphiregulin is closely associated with the sensitivity and resistance of EGFR- TKI treatment. Medicine target on amphiregulin can inhibit the activity of tumors.
出处
《中华胸心血管外科杂志》
CSCD
2017年第2期115-118,共4页
Chinese Journal of Thoracic and Cardiovascular Surgery
